(Repeats to link to news alerts)
LONDON, Jan 29 (Reuters) - AstraZeneca has fixed
most of the issues affecting its European manufacturing and
productivity at its plants there should start to increase, its
chief executive said on Friday.
CEO Pascal Soriot said the company was focused on lifting
production for the European Union after a public dispute over a
shortfall in supplies in the first three months of the year.
"We believe we have fixed most of the issues," Soriot told a
news briefing, adding that productivity should improve rapidly
over the coming months.
(Writing by Keith Weir;
Editing by Hugh Lawson)